- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.10. | TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by Analysts | 2 | MarketBeat | ||
| 25.10. | Northland initiates TriSalus shares with outperform, cites sales growth | 3 | Investing.com | ||
| 25.10. | Northland stuft TriSalus-Aktien mit "Outperform" ein und verweist auf Umsatzwachstum | 1 | Investing.com Deutsch | ||
| 26.09. | TriSalus Life Sciences adds oncology expert to SAB | 1 | Investing.com | ||
| 26.09. | TriSalus Life Sciences erweitert wissenschaftlichen Beirat um Onkologie-Experten | 1 | Investing.com Deutsch | ||
| 23.09. | TriSalus reports breakthrough in liver tumor treatment | 2 | Investing.com | ||
| 16.09. | TriSalus vor Verdopplung? Oppenheimer prognostiziert starkes Kurswachstum | 2 | Investing.com Deutsch | ||
| 16.09. | Oppenheimer initiates TriSalus stock at outperform on liver cancer opportunity | - | Investing.com | ||
| 16.09. | Oppenheimer stuft TriSalus-Aktie mit "Outperform" ein aufgrund von Chancen in der Leberkrebs-Behandlung | 10 | Investing.com Deutsch | ||
| 13.09. | TriSalus Life Sciences CEO buys $75k in company stock | 1 | Investing.com | ||
| 13.09. | TriSalus Life Sciences CEO buys $24,850 in company stock | 1 | Investing.com | ||
| 10.09. | Trisalus Life Sciences director sells shares worth $49 | 1 | Investing.com | ||
| 16.08. | TriSalus stock holds Buy rating with $11 target | 1 | Investing.com | ||
| 15.08. | TriSalus Life Sciences GAAP EPS of -$0.21, revenue of $7.4M | 1 | Seeking Alpha | ||
| 15.08. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.08. | TriSalus Reports Q2 2024 Financial Results and Business Update | 166 | Business Wire | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver... ► Artikel lesen | |
| 01.07. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.06. | TriSalus Life Sciences, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.05. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
| ROCKET LAB USA | 10,440 | -0,76 % | Could Rocket Lab Be a Millionaire-Maker Stock in the Trillion-Dollar Space Industry? | ||
| BOIRON | 32,450 | +1,25 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| MEDICINOVA | 1,600 | 0,00 % | MediciNova, Inc.: MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) | LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| HARROW | 45,500 | +1,97 % | Harrow Unusual Options Activity For October 28 | ||
| ESSA PHARMA | 1,520 | -69,66 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,480 | -0,18 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm | Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm (epinephrine) Sublingual Film to the FDA in the... ► Artikel lesen | |
| SHINECO | 0,134 | +1,36 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,100 | -1,79 % | Cumberland Pharma stock hits 52-week low at $1.18 | ||
| REVIVA PHARMACEUTICALS | 0,995 | -11,16 % | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,262 | -4,62 % | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| NUTRIBAND | 5,600 | +4,67 % | Nutriband, Inc.: Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application | ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled... ► Artikel lesen | |
| BAYER | 25,100 | +1,23 % | Bayer, BASF und Co: Von diesen DAX-Aktien würde jetzt (fast) jeder Analyst die Finger lassen | Von Bayer über BASF bis zu Brenntag und mehr: Sollten Anleger bei diesen DAX-Titeln eher auf Abstand gehen? Zumindest würden fast alle Analysten, die die Aktien beobachten, derzeit keinen Kauf in Erwägung... ► Artikel lesen | |
| MERCK KGAA | 154,05 | +1,35 % | Merck KGaA Aktie: Ein Hin und Her | Merck, der führende Wissenschafts- und Technologiekonzern, kündigte eine bedeutende Investition von 70 Millionen Euro an, um seine Produktionskapazität für Antikörper-Wirkstoff-Konjugate (ADCs) am Standort... ► Artikel lesen |
TRISALUS LIFE SCIENCES INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 3,970 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.
